• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Elucidation of novel mechanism in cardiac fibrosis

Research Project

Project/Area Number 22590815
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Circulatory organs internal medicine
Research InstitutionKinki University

Principal Investigator

IWANAGA Yoshitaka  近畿大学, 医学部, 准教授 (80360816)

Co-Investigator(Renkei-kenkyūsha) ONO Koh  京都大学, 医学研究科, 講師 (00359275)
KOSHIMIZU Taka-aki  自治医科大学, 医学部, 准教授 (20392491)
Project Period (FY) 2010 – 2012
Project Status Completed (Fiscal Year 2012)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords分子心臓病態学 / 心肥大 / 線維化 / 心不全
Research Abstract

We elucidated two novel mechanism in cardiac fibrosis. First, we have shown that metastasis-associated protein, S100A4 mediates pathological cardiac fibrosis through the modulation of p53 in cardiac fibroblast. Second, we have shown that the activation of vasopressin type 1a receptor contributes to the profibrotic effect of angiotensin II in the heart as well as the fibrosis and onset of heart failure seen in pressure-overloaded LV for the first time. In the future, we will investigate whether the modulation of these two factors may offer therapeutic benefits in heart failure.

Report

(4 results)
  • 2012 Annual Research Report   Final Research Report ( PDF )
  • 2011 Annual Research Report
  • 2010 Annual Research Report
  • Research Products

    (12 results)

All 2013 2012 2011 2010 Other

All Journal Article (4 results) (of which Peer Reviewed: 2 results) Presentation (8 results)

  • [Journal Article] Metastasis-associated protein, S100A4 mediates cardiac fibrosis potentially through the modulation of p53 in cardiac fibroblasts2013

    • Author(s)
      Yodo Tamaki, Yoshitaka Iwanaga (Corresponding Author), Shinichiro Niizuma, Tsuneaki Kawashima, Takao Kato, Yasutaka Inuzuka, Takahiro Horie, Hanako Morooka, Toru Takase, Yasumitsu Akahashi, Kazuhiro Kobuke, Koh Ono, Tetsuo Shioi, Soren P Sheikh, Noona Ambartsumian, Eugene Lukanidin, Taka-aki Koshimizu, Shunichi Miyazaki, Takeshi Kimura
    • Journal Title

      J Mol Cell Cardiol

      Volume: 57 Pages: 72-81

    • Related Report
      2012 Final Research Report
  • [Journal Article] Metastasis-associated protein, S100A4 mediates cardiac fibrosis potentially through the modulation of p53 in cardiac fibroblasts.2013

    • Author(s)
      Yodo Tamaki
    • Journal Title

      J Mol Cell Cardiol.

      Volume: 57 Pages: 72-81

    • Related Report
      2012 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Chronic Administration of Oral Vasopressin Type 2 Receptor Antagonist, Tolvaptan Exerts Both Myocardial and Renal Protective Effects in Rats with Hypertensive Heart Failure2012

    • Author(s)
      Hanako Morooka, Yoshitaka Iwanaga (Corresponding Author), Yodo Tamaki, Toru Takase, Yasumitsu Akahoshi, Yasumasa Nakano, Hiroyuki Fujiki, Shunichi Miyazaki
    • Journal Title

      Circ Heart Fail

      Volume: 5 Pages: 484-492

    • Related Report
      2012 Final Research Report
  • [Journal Article] Chronic Administration of Oral Vasopressin Type 2 Receptor Antagonist, Tolvaptan Exerts Both Myocardial and Renal Protective Effects in Rats with Hypertensive Heart Failure.2012

    • Author(s)
      Hanako Morooka
    • Journal Title

      Circ Heart Fail

      Volume: 5

    • Related Report
      2012 Annual Research Report
    • Peer Reviewed
  • [Presentation] Does vasopressin type1a receptor antagonist exert beneficial effects or additive effects to type2 receptor antagonist, tolvaptan in heart failure animals?2013

    • Author(s)
      Tomoyuki Ikeda, Yoshitaka Iwanaga
    • Organizer
      第75回日本循環器学会総会
    • Place of Presentation
      Yokohama, Japan
    • Related Report
      2012 Final Research Report
  • [Presentation] Activation of p53 in Fibroblasts Suppresses Cardiac Fibrosis2012

    • Author(s)
      Y.Tamaki, Y.Iwanaga, et al
    • Organizer
      第76回日本循環器学会学術集会
    • Place of Presentation
      福岡国際会議場
    • Year and Date
      2012-03-17
    • Related Report
      2011 Annual Research Report
  • [Presentation] Interaction of S100A4 with p53 in fibroblasts modulates cardiac fibrosis through two distinct mechanisms2012

    • Author(s)
      Yodo Tamaki, Yoshitaka Iwanaga
    • Organizer
      ESC Congress 2012, Munich
    • Place of Presentation
      Germany
    • Related Report
      2012 Final Research Report
  • [Presentation] Chronic administration of oral vasopressin type 2 receptor blocker, tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure2011

    • Author(s)
      Hanako Morooka, Yoshitaka Iwanaga
    • Organizer
      85th AHA (American Heart Association) Scientific Sessions
    • Place of Presentation
      Orland, USA
    • Related Report
      2012 Final Research Report
  • [Presentation] Vasopressin type la receptor deficiency prevents the onset of heart failure : possible link with myocardial fibrosis.2010

    • Author(s)
      T.Takase, Y.Iwanaga, et al.
    • Organizer
      84th AHA (American Heart Association) Scientific Sessions
    • Place of Presentation
      Chicago, USA
    • Year and Date
      2010-11-17
    • Related Report
      2010 Annual Research Report
  • [Presentation] Vasopressin type 1a receptor deficiency prevents the onset of heart failure: possible link with myocardial fibrosis2010

    • Author(s)
      Toru Takase, Yoshitaka Iwanaga
    • Organizer
      84th AHA (American Heart Association) Scientific Sessions
    • Place of Presentation
      Chicago, USA
    • Related Report
      2012 Final Research Report
  • [Presentation] Interaction of S100A4 with p53 in fibroblasts modulates cardiac fibrosis through two distinct mechanisms.

    • Author(s)
      Yodo Tamaki
    • Organizer
      ESC Congress 2012
    • Place of Presentation
      Munich, Germany
    • Related Report
      2012 Annual Research Report
  • [Presentation] Does vasopressin type1a receptor antagonist exert beneficial effects or additive effects to type2 receptor antagonist, tolvaptan in heart failure animals?

    • Author(s)
      Tomoyuki Ikeda
    • Organizer
      第75回日本循環器学会学術集会
    • Place of Presentation
      Yokohama, Japan
    • Related Report
      2012 Annual Research Report

URL: 

Published: 2010-08-23   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi